Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Corporate & Regulatory

Navigating regulatory compliance review in Russian M&A transactions in the pharmaceuticals sector: a step-by-step overview

Vitaliy Vetrov · June 2026 · 11 min read

Pharmaceutical M&A in Russia triggers multi-regulator compliance reviews. What in-house counsel must verify before signing. Make an enquiry.

Unlike general commercial transactions, pharmaceutical M&A in Russia activates a distinct layer of regulatory compliance review that sits above and alongside the standard civil-law due diligence framework. Foreign acquirers – whether purchasing a Russian pharmaceutical manufacturer, a distribution network, or a marketing authorisation portfolio – encounter a multi-regulator environment in which Roszdravnadzor, the Federal Antimonopoly Service, the Ministry of Industry and Trade, and the EAEU registration bodies each hold a veto right over specific elements of the transaction. The practical consequence is that deal timelines are driven less by negotiation than by regulatory sequencing, and in-house counsel who apply a standard corporate due diligence checklist to a Russian pharma target frequently find that the most commercially significant risks are precisely those that checklist did not cover.

What to prepare before starting regulatory compliance review

Before engaging with any regulator or counterparty, a structured document preparation phase substantially reduces the risk of gap-discoveries mid-process. The following items form the baseline of any pharmaceutical M&A regulatory compliance review in Russia.

If your team is assembling the document request list for a Russian pharmaceutical target, make an enquiry: info@vetrovpartners.com |

Step 1 — Map the regulatory perimeter before reviewing documents

The first substantive step in any pharmaceutical regulatory compliance review in Russia is to establish which regulatory regimes apply to the specific transaction structure – and in what sequence they must be addressed. This step is frequently skipped by deal teams under time pressure, and the consequence is typically a late-stage discovery of a consent requirement that renegotiates the deal timeline.

The regulatory perimeter for a Russian pharmaceutical M&A transaction typically spans four distinct bodies. Roszdravnadzor controls licensing for manufacture, wholesale, and retail distribution of medicines. The Ministry of Industry and Trade holds authority over GMP certification and, for domestically manufactured pharmaceuticals, the localisation regime under current industrial policy. FAS Russia has jurisdiction over merger control when the turnover thresholds are met, and also reviews transactions in markets defined as strategically significant. The EAEU dimension applies where the target holds registrations under the unified procedure: changes to the registration holder require a separate administrative process with the EAEU Council.

In practice, these regimes do not run in parallel on the same timeline. GMP re-certification following an ownership change can take several months under standard procedures, and that timeline may govern when the licences formally transfer. Mapping the perimeter at the outset allows deal counsel to identify the critical-path regulator – the one whose consent or process takes longest – and structure the signing-to-closing mechanics around it.

Step 2 — Conduct the licensing and marketing authorisation review

The core of regulatory compliance review in Russian pharmaceutical M&A is the licence and marketing authorisation audit. The commercial value of a pharmaceutical business in Russia is largely a function of the regulatory assets it holds, and those assets are more fragile than they appear on a document schedule.

Russian pharmaceutical licences are issued to a specific legal entity at a specific address for a specific scope of activity. A change of ownership does not automatically transfer a licence; nor does it invalidate one, unless the change triggers a notification or re-application obligation. The practical risk is that a target's licences may have been issued under conditions – particular premises, equipment, staffing levels – that the acquirer cannot replicate or has not verified. An in-house counsel reviewing a licence schedule should ask not only whether the licences are current but whether the conditions underlying them remain satisfied.

Marketing authorisations present a related but distinct risk. State registration of a medicine in Russia is held by a legal entity – in most cases, either the foreign manufacturer directly or a Russian representative. Where the target acts as the Russian registration holder for a foreign principal's products, the acquisition raises an immediate question about change-of-holder procedure. This process involves a formal application to Roszdravnadzor and can run concurrently with the transaction, but it must begin early; delays have commercially material consequences where the registration is linked to tender participation or hospital supply contracts.

The review at this step should also capture any products whose registrations are approaching expiry. Re-registration under current Russian pharmaceutical legislation involves a more extensive review than the initial registration, and targets sometimes carry a tail of registrations whose renewal is overdue.

Step 3 — Assess GMP compliance and the manufacturing authorisation position

For transactions involving a manufacturing target, GMP compliance is the most operationally significant element of the regulatory compliance review. A Russian pharmaceutical manufacturer must hold a valid GMP certificate issued by the Ministry of Industry and Trade, and that certificate is tied to specific production sites, dosage forms, and manufacturing lines. The certificate is not transferred with the shares; following closing, the new owner must notify the Ministry and, in many circumstances, submit to a re-inspection before the certificate is renewed in the acquirer's name.

The practical consequence of a GMP gap – a period in which the manufacturing authorisation is not validly held – is production stoppage. For a target with ongoing supply obligations under government contracts or hospital procurement frameworks, even a brief interruption carries penalties and reputational consequences that can materially affect post-acquisition value. Foreign acquirers who have completed similar transactions in other jurisdictions often underestimate this risk because GMP certification in many other markets is handled differently.

Note: In-house counsel should verify whether the target's current GMP certificate is subject to any suspension, limitation, or condition note issued following a Roszdravnadzor or Ministry of Industry and Trade inspection. An uncured inspection finding does not always appear on the face of the certificate – it may exist as a separate administrative act in the regulator's file. A thorough regulatory compliance review will include a request for all inspection documentation over the preceding five years, not merely the current certificate.

The localisation angle also falls within this step where relevant. Under current Russian industrial policy, certain public procurement preferences apply to pharmaceuticals manufactured locally or under qualifying localisation agreements. Where the target's commercial position depends on these preferences, the acquirer should verify the conditions of the localisation agreement and whether they survive a change of control.

Step 4 — Address FAS Russia merger control and sector-specific review

Antitrust pre-clearance from FAS Russia is a binding condition to closing where the relevant thresholds are met, and pharmaceutical transactions frequently meet them due to the combination of the target's asset value, its market share in specific therapeutic areas, and, in some cases, the strategic-importance designation of the market. FAS clearance in pharmaceutical transactions is not a formality: the agency applies a substantive market-definition analysis, and in markets characterised by significant concentration – certain segments of the hospital supply or oncology markets, for example – it may attach behavioural conditions or require asset divestment.

The FAS review also covers foreign control aspects. Transactions in which a foreign entity acquires control over a Russian pharmaceutical company may trigger an additional review layer under Russian legislation governing strategic sectors. Pharmaceutical manufacturing has at various points been within the perimeter of that regime, though the precise scope is subject to regulatory interpretation and has changed over time. Counsel should confirm the current position at the outset of the transaction rather than assuming the prior-deal precedent still holds.

The timing implication is significant. FAS Russia has a defined statutory review period for merger filings, but that period may be extended in cases involving complex market analysis or strategic-sector referral. Acquirers who file for FAS clearance only after satisfying themselves on the licence and GMP position may find that the total pre-closing timeline is longer than anticipated. In practice, the FAS filing should be prepared in parallel with the document review, not sequentially.

For in-house counsel managing a Russian pharmaceutical acquisition where FAS clearance and licensing timelines run in parallel, structuring the process requires experienced local coordination. Make an enquiry: info@vetrovpartners.com |

Step 5 — Verify EAEU regulatory exposure and cross-border compliance obligations

For pharmaceutical companies operating across EAEU member states – Russia, Belarus, Kazakhstan, Armenia, and the Kyrgyz Republic – the transaction may engage the EAEU unified registration procedure in addition to Russian national requirements. This dimension is frequently overlooked in deals that are structured around the Russian entity alone.

Where the target holds medicines registered under the EAEU unified procedure, the registration is recognised across all member states and the registration holder carries compliance obligations in each. A change in the Russian holding entity affects the EAEU registration record, and the procedure for updating the registration holder at the EAEU level is separate from – and does not follow automatically from – the Russian national process. This creates a sequencing risk: a purchaser who has completed the national procedure in Russia may find that the EAEU registrations are temporarily out of name alignment, which can affect regulatory standing in other member states.

Additionally, the target's import and distribution arrangements in CIS markets may carry their own change-of-control provisions. Where the transaction involves a Russian company that acts as the regional distribution anchor for a multinational's product portfolio, the acquirer should review all principal agreements for consent requirements and, where consent is needed, begin that process before signing.

The EAEU compliance review is most efficiently conducted alongside – not after – the Russian national licensing review, because the documentary record overlaps substantially. A single document request to the target can capture both streams, provided the review scope is designed to cover them.

Frequently asked questions

Q: How long does a full regulatory compliance review typically take in a Russian pharmaceutical M&A transaction?

A: The timeline varies with the complexity of the target's regulatory portfolio, but in practice a substantive review covering licensing, marketing authorisations, GMP compliance, and FAS pre-clearance preparation commonly takes between six and twelve weeks from the date the target produces a complete document package. The critical variable is not the legal analysis but the completeness of the target's records: gaps in inspection documentation or missing EAEU registration files extend the review materially. For transactions with a tight signing deadline, a phased approach – red-flag review first, full review before closing – allows the deal to progress while the regulatory picture is still being assembled.

Q: Which Russian regulator poses the greatest compliance risk for a foreign acquirer in the pharmaceutical sector?

A: The answer depends on the target's profile, but in transactions involving a manufacturer, the Ministry of Industry and Trade's GMP certification process is typically the longest-lead item and therefore the highest-risk regulator from a deal-timing perspective. For distribution-only businesses, Roszdravnadzor's licensing conditions and marketing authorisation re-registration are more central. FAS Russia is the critical constraint in concentrated market segments. In-house counsel should assess which regulator controls the critical-path consent at the outset rather than treating the review as a sequential checklist.

Q: Can a Russian pharmaceutical licence be transferred as part of a share deal?

A: In a share deal, the licensed entity continues to exist as the same legal person and the licences formally remain in place. However, the practical position is more nuanced. Roszdravnadzor's licensing regulations require notification of certain changes – including changes in beneficial ownership above defined thresholds – and failure to notify can result in a compliance finding even where the licence was not formally suspended. Additionally, if the acquisition alters the conditions underlying the licence (premises, responsible personnel, equipment), a variation application may be required. A regulatory compliance review should map the notification and variation obligations specific to each licence held by the target, not assume that the share deal structure insulates the acquirer from licensing exposure.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry